UB Paderborn / Katalog / Suche / in CDI

Sortiert nach

Einfacher Volltextzugriff von (fast) überall

Installieren Sie die LibKey Nomad-Browsererweiterung und erhalten Sie von vielen Webseiten einfachen Zugriff auf lizenzierte Volltexte oder Open Access Publikationen. Mehr erfahren...

GLP2-2G-XTEN: a pharmaceutical protein with improved serum half-life and efficacy in a rat Crohn's disease model

PloS one, 2012-11, Vol.7 (11), p.e50630

2012

Volltextzugriff (PDF)

Systemic depletion of L-cyst(e)ine with cyst(e)inase increases reactive oxygen species and suppresses tumor growth

Nature medicine, 2017-01, Vol.23 (1), p.120-127

2017

Volltextzugriff (PDF)

Preclinical safety and antitumor activity of the arginine-degrading therapeutic enzyme pegzilarginase, a PEGylated, cobalt-substituted recombinant human arginase 1

Translational research : the journal of laboratory and clinical medicine, 2020-03, Vol.217, p.11-22

2020

Volltextzugriff (PDF)

Selective Tumor Targeting by the Hypoxia-Activated Prodrug AQ4N Blocks Tumor Growth and Metastasis in Preclinical Models of Pancreatic Cancer

Clinical cancer research, 2007-04, Vol.13 (7), p.2216-2225

2007

Volltextzugriff (PDF)

GLP2-2G-XTEN: a pharmaceutical protein with improved serum half-life and efficacy in a rat Crohn's. PLoS One. 2012; 7(11): e50630

PloS one, 2013, Vol.8 (6)

2013

Volltextzugriff (PDF)

Human recombinant arginase enzyme reduces plasma arginine in mouse models of arginase deficiency

Human molecular genetics, 2015-11, Vol.24 (22), p.6417-6427

2015

Volltextzugriff (PDF)

A Novel Long-Acting Human Growth Hormone Fusion Protein (VRS-317): Enhanced In Vivo Potency and Half-Life

Journal of pharmaceutical sciences, 2012-08, Vol.101 (8), p.2744-2754

2012

Volltextzugriff (PDF)

Correction: GLP2-2G-XTEN: A Pharmaceutical Protein with Improved Serum Half-Life and Efficacy in a Rat Crohn’s Disease Model

PloS one, 2013-06, Vol.8 (6)

2013

Volltextzugriff (PDF)

Immune systems biology: immunoprofiling of cells and molecules

BioTechniques, 2004-03, Vol.36 (3), p.520-524

2004

Volltextzugriff (PDF)

Abstract 3964: Reducing systemic arginine with arginase (AEB1102) therapy does not suppress the immune response induced by anti-PD-1 and anti-PD-L1, and exerts an additive anti-tumor and synergistic survival benefit

Cancer research (Chicago, Ill.), 2017-07, Vol.77 (13_Supplement), p.3964-3964

2017

Volltextzugriff (PDF)

Abstract 1624: eIF4E allosteric regulators cause rapid commitment to apoptosis in cancer cells while sparing immune cells

Cancer research (Chicago, Ill.), 2023-04, Vol.83 (7_Supplement), p.1624-1624

2023

Volltextzugriff (PDF)

Abstract CT030: Phase I dose escalation trial of pegzilarginase in patients with advanced solid tumors

Cancer research (Chicago, Ill.), 2018-07, Vol.78 (13_Supplement), p.CT030-CT030

2018

Volltextzugriff (PDF)

Abstract LB208: A potent macrophage switching drug D-4559 reduces tumor GROWTH in a hepatocellular carcinoma mouse model

Cancer research (Chicago, Ill.), 2023-04, Vol.83 (8_Supplement), p.LB208-LB208

2023

Volltextzugriff (PDF)

Enhancement of the efficacy of an antagonist of an extracellular receptor by attachment to the surface of a biocompatible carrier

Pharmaceutical research, 2004-10, Vol.21 (10), p.1880-1885

2004

Volltextzugriff (PDF)

Abstract 1042: Development of AEB1102, an engineered human arginase 1 for patients with solid tumors

Cancer research (Chicago, Ill.), 2016-07, Vol.76 (14_Supplement), p.1042-1042

2016

Volltextzugriff (PDF)

Systemic depletion of L-cystinase increases reactive oxygen species and suppresses tumor growth

Nature medicine, 2017-01, Vol.23 (1), p.120

2017

Volltextzugriff (PDF)

Systemic depletion of serum l-Cyst(e)ine with an engineered human enzyme induces production of reactive oxygen species and suppresses tumor growth in mice

Nature medicine, 2016-11, Vol.23 (1), p.120-127

2016

Volltextzugriff (PDF)

The Prodrug AQ4N Displays Potent Anti-Tumor Activity in a Xenotransplantation Model of Primary Human Acute Lymphoblastic Leukemia

Blood, 2005-11, Vol.106 (11), p.1837-1837

2005

Volltextzugriff (PDF)

A Novel N-Oxide Drug, AQ4N, Has In Vitro Activity in Lymphoma and Leukemia Cell Lines and Selectively Targets Lymphocytes and Lymphatic Tissues in Vivo

Blood, 2004-11, Vol.104 (11), p.2498-2498

2004

Volltextzugriff (PDF)

Dendritic cells loaded with MART-1 peptide or infected with adenoviral construct are functionally equivalent in the induction of tumor-specific cytotoxic T lymphocyte responses in patients with melanoma

Journal of immunotherapy, 2000-01, Vol.23 (1), p.168-176

2000

Volltextzugriff (PDF)

Dendritic cells pulsed with CEA peptide induce CEA-specific CTL with restricted TCR repertoire

Journal of immunotherapy, 1998-01, Vol.21 (1), p.17-26

1998

Volltextzugriff (PDF)

IL-13 can substitute for IL-4 in the generation of dendritic cells for the induction of cytotoxic T lymphocytes and gene therapy

Journal of immunotherapy, 1999-05, Vol.22 (3), p.229-236

1999

Volltextzugriff (PDF)

Anti-CD4 mediates clonal anergy during transplantation tolerance induction

The Journal of experimental medicine, 1991-02, Vol.173 (2), p.491-494

1991

Volltextzugriff (PDF)

Immunotherapy of cancer. Generation of CEA specific CTL using CEA peptide pulsed dendritic cells

Advances in experimental medicine and biology, 1997, Vol.417, p.519

1997

Volltextzugriff (PDF)

Phenotypic profiling of blood and airway secretions in asthmatic and healthy subjects

Journal of allergy and clinical immunology, 2002, Vol.109 (1), p.S119-S119

2002

Volltextzugriff (PDF)

1 – 25 von 44

Suche als RSS-Feed

Suchergebnisse filtern

Filter anzeigen

Nur zeigen

Geprüft (Peer-Review)
(38)
Mit Volltextzugriff
(32)

Publikationsform

Sprache

Englisch
(44)

Erscheinungsjahr

n.n

Thema

Science & Technology
(28)
Life Sciences & Biomedicine
(27)
Humans
(22)
Biological And Medical Sciences
(16)
Animals
(15)
Female
(14)
Male
(13)
Medical Sciences
(12)
Mice
(12)
Immunology
(11)
Medicine, Research & Experimental
(8)
Research & Experimental Medicine
(8)
Child, Preschool
(7)
Child
(6)
Cd4 Antigens - Immunology
(5)
Disease Models, Animal
(5)
Miscellaneous
(5)
Oncology
(5)
Ophthalmology
(5)
T-Lymphocytes, Cytotoxic - Immunology
(5)

15 weitere anzeigen...

Weniger anzeigen...

Zeitschrift / Serie

Cancer Research
(5)
Archives Of Ophthalmology
(3)
Journal Of Immunotherapy
(3)
Nature Medicine
(3)
Plos One
(3)
Transplantation
(3)
Blood
(2)
Journal Of Autoimmunity
(2)
Ophthalmology
(2)
Advances In Experimental Medicine And Biology
(1)

5 weitere anzeigen...

Weniger anzeigen...

Menü

Weitere Dienste

Einstellungen

GLP2-2G-XTEN: a pharmaceutical protein with improved serum half-life and efficacy in a rat Crohn's disease model

Systemic depletion of L-cyst(e)ine with cyst(e)inase increases reactive oxygen species and suppresses tumor growth

Preclinical safety and antitumor activity of the arginine-degrading therapeutic enzyme pegzilarginase, a PEGylated, cobalt-substituted recombinant human arginase 1

Selective Tumor Targeting by the Hypoxia-Activated Prodrug AQ4N Blocks Tumor Growth and Metastasis in Preclinical Models of Pancreatic Cancer

GLP2-2G-XTEN: a pharmaceutical protein with improved serum half-life and efficacy in a rat Crohn's. PLoS One. 2012; 7(11): e50630

Human recombinant arginase enzyme reduces plasma arginine in mouse models of arginase deficiency

A Novel Long-Acting Human Growth Hormone Fusion Protein (VRS-317): Enhanced In Vivo Potency and Half-Life

Correction: GLP2-2G-XTEN: A Pharmaceutical Protein with Improved Serum Half-Life and Efficacy in a Rat Crohn’s Disease Model

Immune systems biology: immunoprofiling of cells and molecules

Abstract 3964: Reducing systemic arginine with arginase (AEB1102) therapy does not suppress the immune response induced by anti-PD-1 and anti-PD-L1, and exerts an additive anti-tumor and synergistic survival benefit

Abstract 1624: eIF4E allosteric regulators cause rapid commitment to apoptosis in cancer cells while sparing immune cells

Abstract CT030: Phase I dose escalation trial of pegzilarginase in patients with advanced solid tumors

Abstract LB208: A potent macrophage switching drug D-4559 reduces tumor GROWTH in a hepatocellular carcinoma mouse model

Enhancement of the efficacy of an antagonist of an extracellular receptor by attachment to the surface of a biocompatible carrier

Abstract 1042: Development of AEB1102, an engineered human arginase 1 for patients with solid tumors

Systemic depletion of L-cystinase increases reactive oxygen species and suppresses tumor growth

Systemic depletion of serum l-Cyst(e)ine with an engineered human enzyme induces production of reactive oxygen species and suppresses tumor growth in mice

The Prodrug AQ4N Displays Potent Anti-Tumor Activity in a Xenotransplantation Model of Primary Human Acute Lymphoblastic Leukemia

A Novel N-Oxide Drug, AQ4N, Has In Vitro Activity in Lymphoma and Leukemia Cell Lines and Selectively Targets Lymphocytes and Lymphatic Tissues in Vivo

Dendritic cells loaded with MART-1 peptide or infected with adenoviral construct are functionally equivalent in the induction of tumor-specific cytotoxic T lymphocyte responses in patients with melanoma

Dendritic cells pulsed with CEA peptide induce CEA-specific CTL with restricted TCR repertoire

IL-13 can substitute for IL-4 in the generation of dendritic cells for the induction of cytotoxic T lymphocytes and gene therapy

Anti-CD4 mediates clonal anergy during transplantation tolerance induction

Immunotherapy of cancer. Generation of CEA specific CTL using CEA peptide pulsed dendritic cells

Phenotypic profiling of blood and airway secretions in asthmatic and healthy subjects

Suchergebnisse filtern